| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.092 | 0.006 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.006 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.006 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.007 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.007 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.41 | 0.007 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.008 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.097 | 0.008 |